@article{110ae37e05554370af98399881ee45d1,
title = "Recent progress concerning CpG DNA and its use as a vaccine adjuvant",
abstract = "CpG Oligonucleotides (ODN) are immunomodulatory synthetic oligonucleotides designed to specifically agonize Toll-like receptor 9. Here, we review recent progress in understanding the mechanism of action of CpG ODN and provide an overview of human clinical trial results using CpG ODN to improve the vaccines for cancer, allergy and infectious disease.",
keywords = "CpG oligonucleotide, Toll-like receptor, allergy, cancer, infection, vaccine adjuvant",
author = "Hidekazu Shirota and Klinman, {Dennis M.}",
note = "Funding Information: DM Klinman and members of his laboratory are inventors/co-inventors on a number of patents pertaining to CpG ODN. All rights to these patents have been assigned to the Federal Government. This work was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Funding Information: This work was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute. The assertions herein are the private ones of the authors and are not to be construed as official or as reflecting the views of the National Cancer Institute at large.",
year = "2014",
month = feb,
doi = "10.1586/14760584.2014.863715",
language = "English",
volume = "13",
pages = "299--312",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "2",
}
